Global Human Microbiome

Human Microbiome Comprehensive Study by Type (Probiotics, Prebiotics, Food, Medical Foods, Devices, Drugs), Application (Therapeutics, Diagnostics), Disease (Infectious Diseases, Endocrine and Metabolic Disorders, Inflammatory Diseases, Cancer, Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders}), Technology (Sequencing, Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}, Proteomics, Metabolomics) Players and Region - Global Market Outlook to 2030

Human Microbiome Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 31%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Human Microbiome
The microbiome is important for nutrition immunity as well as human development. The human microbiome is also known as the collective genomes of resident microorganisms. It not only helps to digest our food but also regulate our immune system. In addition, it also helps to protect against other bacteria that cause disease in the human body. It also produces various vitamins such as Vitamin K, vitamins B12, riboflavin, and others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR31.0%


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market shortly. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period.The Players having a strong hold in the market are Enterome Bioscience (France), Seres Therapeutics (United States), and 4D Pharma (United Kingdom. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Human Microbiome market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Seres Therapeutics (United States), Pharma PLC (United Kingdom), UBiome (United States), E.I. du Pont de Nemours and Company (United States), Synlogic (United States), Second Genome (United States), Vedanta Biosciences (United States) and Ferring Pharmaceuticals (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Evelo Biosciences (United States), ViThera Pharmaceuticals (United States), BiomX (Israel) and LNC Therapeutics (France).

Segmentation Overview
AMA Research has segmented the market of Global Human Microbiome market by Type (Probiotics, Prebiotics, Food, Medical Foods, Devices and Drugs), Application (Therapeutics and Diagnostics) and Region.



On the basis of geography, the market of Human Microbiome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease, the sub-segment i.e. Infectious Diseases will boost the Human Microbiome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Sequencing will boost the Human Microbiome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Number of Microbiome-Based Drug Pipeline Across the Worldwide

Market Growth Drivers:
Augmented Focus on Human Microbiome Therapy Development and Growing Focus of Biotech Companies on Life Science Research Worldwide

Challenges:
Lack of Expertise as well as Detailed Research

Restraints:
Barriers in Proving the Causal Link between Dysbiosis and Disease

Opportunities:
Growing Demand from Emerging Market such as China, India, among others

Market Leaders and their expansionary development strategies
In October 2023, Clinical Microbiomics A/S and CosmosID Inc. merged to create a global leader in microbiome research services. This merger aims to accelerate standardization in microbiome research and provide access to local GxP laboratories.
In 2020, the Seres Company has collaborated with AstraZeneca, which will help to get a better microbiome in augmenting the efficacy of cancer immunotherapy. Hence, this microbiome will affect the growth of the market in the future.


Key Target Audience
Human Microbiome Manufacturers, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Raw Material Suppliers

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Probiotics
  • Prebiotics
  • Food
  • Medical Foods
  • Devices
  • Drugs
By Application
  • Therapeutics
  • Diagnostics
By Disease
  • Infectious Diseases
  • Endocrine and Metabolic Disorders
  • Inflammatory Diseases
  • Cancer
  • Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders}

By Technology
  • Sequencing
  • Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
  • Proteomics
  • Metabolomics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Augmented Focus on Human Microbiome Therapy Development
      • 3.2.2. Growing Focus of Biotech Companies on Life Science Research Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Lack of Expertise as well as Detailed Research
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Microbiome-Based Drug Pipeline Across the Worldwide
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Microbiome, by Type, Application, Disease, Technology and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Microbiome (Value)
      • 5.2.1. Global Human Microbiome by: Type (Value)
        • 5.2.1.1. Probiotics
        • 5.2.1.2. Prebiotics
        • 5.2.1.3. Food
        • 5.2.1.4. Medical Foods
        • 5.2.1.5. Devices
        • 5.2.1.6. Drugs
      • 5.2.2. Global Human Microbiome by: Application (Value)
        • 5.2.2.1. Therapeutics
        • 5.2.2.2. Diagnostics
      • 5.2.3. Global Human Microbiome by: Disease (Value)
        • 5.2.3.1. Infectious Diseases
        • 5.2.3.2. Endocrine and Metabolic Disorders
        • 5.2.3.3. Inflammatory Diseases
        • 5.2.3.4. Cancer
        • 5.2.3.5. Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders}
      • 5.2.4. Global Human Microbiome by: Technology (Value)
        • 5.2.4.1. Sequencing
        • 5.2.4.2. Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
        • 5.2.4.3. Proteomics
        • 5.2.4.4. Metabolomics
      • 5.2.5. Global Human Microbiome Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Human Microbiome (Volume)
      • 5.3.1. Global Human Microbiome by: Type (Volume)
        • 5.3.1.1. Probiotics
        • 5.3.1.2. Prebiotics
        • 5.3.1.3. Food
        • 5.3.1.4. Medical Foods
        • 5.3.1.5. Devices
        • 5.3.1.6. Drugs
      • 5.3.2. Global Human Microbiome by: Application (Volume)
        • 5.3.2.1. Therapeutics
        • 5.3.2.2. Diagnostics
      • 5.3.3. Global Human Microbiome by: Disease (Volume)
        • 5.3.3.1. Infectious Diseases
        • 5.3.3.2. Endocrine and Metabolic Disorders
        • 5.3.3.3. Inflammatory Diseases
        • 5.3.3.4. Cancer
        • 5.3.3.5. Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders}
      • 5.3.4. Global Human Microbiome by: Technology (Volume)
        • 5.3.4.1. Sequencing
        • 5.3.4.2. Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
        • 5.3.4.3. Proteomics
        • 5.3.4.4. Metabolomics
      • 5.3.5. Global Human Microbiome Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Human Microbiome (Price)
      • 5.4.1. Global Human Microbiome by: Type (Price)
  • 6. Human Microbiome: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Seres Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pharma PLC (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. UBiome (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. E.I. du Pont de Nemours and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Synlogic (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Second Genome (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vedanta Biosciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ferring Pharmaceuticals (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Human Microbiome Sale, by Type, Application, Disease, Technology and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Microbiome (Value)
      • 7.2.1. Global Human Microbiome by: Type (Value)
        • 7.2.1.1. Probiotics
        • 7.2.1.2. Prebiotics
        • 7.2.1.3. Food
        • 7.2.1.4. Medical Foods
        • 7.2.1.5. Devices
        • 7.2.1.6. Drugs
      • 7.2.2. Global Human Microbiome by: Application (Value)
        • 7.2.2.1. Therapeutics
        • 7.2.2.2. Diagnostics
      • 7.2.3. Global Human Microbiome by: Disease (Value)
        • 7.2.3.1. Infectious Diseases
        • 7.2.3.2. Endocrine and Metabolic Disorders
        • 7.2.3.3. Inflammatory Diseases
        • 7.2.3.4. Cancer
        • 7.2.3.5. Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders}
      • 7.2.4. Global Human Microbiome by: Technology (Value)
        • 7.2.4.1. Sequencing
        • 7.2.4.2. Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
        • 7.2.4.3. Proteomics
        • 7.2.4.4. Metabolomics
      • 7.2.5. Global Human Microbiome Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Human Microbiome (Volume)
      • 7.3.1. Global Human Microbiome by: Type (Volume)
        • 7.3.1.1. Probiotics
        • 7.3.1.2. Prebiotics
        • 7.3.1.3. Food
        • 7.3.1.4. Medical Foods
        • 7.3.1.5. Devices
        • 7.3.1.6. Drugs
      • 7.3.2. Global Human Microbiome by: Application (Volume)
        • 7.3.2.1. Therapeutics
        • 7.3.2.2. Diagnostics
      • 7.3.3. Global Human Microbiome by: Disease (Volume)
        • 7.3.3.1. Infectious Diseases
        • 7.3.3.2. Endocrine and Metabolic Disorders
        • 7.3.3.3. Inflammatory Diseases
        • 7.3.3.4. Cancer
        • 7.3.3.5. Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders}
      • 7.3.4. Global Human Microbiome by: Technology (Volume)
        • 7.3.4.1. Sequencing
        • 7.3.4.2. Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays}
        • 7.3.4.3. Proteomics
        • 7.3.4.4. Metabolomics
      • 7.3.5. Global Human Microbiome Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Human Microbiome (Price)
      • 7.4.1. Global Human Microbiome by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Microbiome: by Type(USD Million)
  • Table 2. Human Microbiome Probiotics , by Region USD Million (2018-2023)
  • Table 3. Human Microbiome Prebiotics , by Region USD Million (2018-2023)
  • Table 4. Human Microbiome Food , by Region USD Million (2018-2023)
  • Table 5. Human Microbiome Medical Foods , by Region USD Million (2018-2023)
  • Table 6. Human Microbiome Devices , by Region USD Million (2018-2023)
  • Table 7. Human Microbiome Drugs , by Region USD Million (2018-2023)
  • Table 8. Human Microbiome: by Application(USD Million)
  • Table 9. Human Microbiome Therapeutics , by Region USD Million (2018-2023)
  • Table 10. Human Microbiome Diagnostics , by Region USD Million (2018-2023)
  • Table 11. Human Microbiome: by Disease(USD Million)
  • Table 12. Human Microbiome Infectious Diseases , by Region USD Million (2018-2023)
  • Table 13. Human Microbiome Endocrine and Metabolic Disorders , by Region USD Million (2018-2023)
  • Table 14. Human Microbiome Inflammatory Diseases , by Region USD Million (2018-2023)
  • Table 15. Human Microbiome Cancer , by Region USD Million (2018-2023)
  • Table 16. Human Microbiome Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders} , by Region USD Million (2018-2023)
  • Table 17. Human Microbiome: by Technology(USD Million)
  • Table 18. Human Microbiome Sequencing , by Region USD Million (2018-2023)
  • Table 19. Human Microbiome Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays} , by Region USD Million (2018-2023)
  • Table 20. Human Microbiome Proteomics , by Region USD Million (2018-2023)
  • Table 21. Human Microbiome Metabolomics , by Region USD Million (2018-2023)
  • Table 22. South America Human Microbiome, by Country USD Million (2018-2023)
  • Table 23. South America Human Microbiome, by Type USD Million (2018-2023)
  • Table 24. South America Human Microbiome, by Application USD Million (2018-2023)
  • Table 25. South America Human Microbiome, by Disease USD Million (2018-2023)
  • Table 26. South America Human Microbiome, by Technology USD Million (2018-2023)
  • Table 27. Brazil Human Microbiome, by Type USD Million (2018-2023)
  • Table 28. Brazil Human Microbiome, by Application USD Million (2018-2023)
  • Table 29. Brazil Human Microbiome, by Disease USD Million (2018-2023)
  • Table 30. Brazil Human Microbiome, by Technology USD Million (2018-2023)
  • Table 31. Argentina Human Microbiome, by Type USD Million (2018-2023)
  • Table 32. Argentina Human Microbiome, by Application USD Million (2018-2023)
  • Table 33. Argentina Human Microbiome, by Disease USD Million (2018-2023)
  • Table 34. Argentina Human Microbiome, by Technology USD Million (2018-2023)
  • Table 35. Rest of South America Human Microbiome, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Human Microbiome, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Human Microbiome, by Disease USD Million (2018-2023)
  • Table 38. Rest of South America Human Microbiome, by Technology USD Million (2018-2023)
  • Table 39. Asia Pacific Human Microbiome, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Human Microbiome, by Type USD Million (2018-2023)
  • Table 41. Asia Pacific Human Microbiome, by Application USD Million (2018-2023)
  • Table 42. Asia Pacific Human Microbiome, by Disease USD Million (2018-2023)
  • Table 43. Asia Pacific Human Microbiome, by Technology USD Million (2018-2023)
  • Table 44. China Human Microbiome, by Type USD Million (2018-2023)
  • Table 45. China Human Microbiome, by Application USD Million (2018-2023)
  • Table 46. China Human Microbiome, by Disease USD Million (2018-2023)
  • Table 47. China Human Microbiome, by Technology USD Million (2018-2023)
  • Table 48. Japan Human Microbiome, by Type USD Million (2018-2023)
  • Table 49. Japan Human Microbiome, by Application USD Million (2018-2023)
  • Table 50. Japan Human Microbiome, by Disease USD Million (2018-2023)
  • Table 51. Japan Human Microbiome, by Technology USD Million (2018-2023)
  • Table 52. India Human Microbiome, by Type USD Million (2018-2023)
  • Table 53. India Human Microbiome, by Application USD Million (2018-2023)
  • Table 54. India Human Microbiome, by Disease USD Million (2018-2023)
  • Table 55. India Human Microbiome, by Technology USD Million (2018-2023)
  • Table 56. South Korea Human Microbiome, by Type USD Million (2018-2023)
  • Table 57. South Korea Human Microbiome, by Application USD Million (2018-2023)
  • Table 58. South Korea Human Microbiome, by Disease USD Million (2018-2023)
  • Table 59. South Korea Human Microbiome, by Technology USD Million (2018-2023)
  • Table 60. Taiwan Human Microbiome, by Type USD Million (2018-2023)
  • Table 61. Taiwan Human Microbiome, by Application USD Million (2018-2023)
  • Table 62. Taiwan Human Microbiome, by Disease USD Million (2018-2023)
  • Table 63. Taiwan Human Microbiome, by Technology USD Million (2018-2023)
  • Table 64. Australia Human Microbiome, by Type USD Million (2018-2023)
  • Table 65. Australia Human Microbiome, by Application USD Million (2018-2023)
  • Table 66. Australia Human Microbiome, by Disease USD Million (2018-2023)
  • Table 67. Australia Human Microbiome, by Technology USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Human Microbiome, by Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Human Microbiome, by Application USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Human Microbiome, by Disease USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Human Microbiome, by Technology USD Million (2018-2023)
  • Table 72. Europe Human Microbiome, by Country USD Million (2018-2023)
  • Table 73. Europe Human Microbiome, by Type USD Million (2018-2023)
  • Table 74. Europe Human Microbiome, by Application USD Million (2018-2023)
  • Table 75. Europe Human Microbiome, by Disease USD Million (2018-2023)
  • Table 76. Europe Human Microbiome, by Technology USD Million (2018-2023)
  • Table 77. Germany Human Microbiome, by Type USD Million (2018-2023)
  • Table 78. Germany Human Microbiome, by Application USD Million (2018-2023)
  • Table 79. Germany Human Microbiome, by Disease USD Million (2018-2023)
  • Table 80. Germany Human Microbiome, by Technology USD Million (2018-2023)
  • Table 81. France Human Microbiome, by Type USD Million (2018-2023)
  • Table 82. France Human Microbiome, by Application USD Million (2018-2023)
  • Table 83. France Human Microbiome, by Disease USD Million (2018-2023)
  • Table 84. France Human Microbiome, by Technology USD Million (2018-2023)
  • Table 85. Italy Human Microbiome, by Type USD Million (2018-2023)
  • Table 86. Italy Human Microbiome, by Application USD Million (2018-2023)
  • Table 87. Italy Human Microbiome, by Disease USD Million (2018-2023)
  • Table 88. Italy Human Microbiome, by Technology USD Million (2018-2023)
  • Table 89. United Kingdom Human Microbiome, by Type USD Million (2018-2023)
  • Table 90. United Kingdom Human Microbiome, by Application USD Million (2018-2023)
  • Table 91. United Kingdom Human Microbiome, by Disease USD Million (2018-2023)
  • Table 92. United Kingdom Human Microbiome, by Technology USD Million (2018-2023)
  • Table 93. Netherlands Human Microbiome, by Type USD Million (2018-2023)
  • Table 94. Netherlands Human Microbiome, by Application USD Million (2018-2023)
  • Table 95. Netherlands Human Microbiome, by Disease USD Million (2018-2023)
  • Table 96. Netherlands Human Microbiome, by Technology USD Million (2018-2023)
  • Table 97. Rest of Europe Human Microbiome, by Type USD Million (2018-2023)
  • Table 98. Rest of Europe Human Microbiome, by Application USD Million (2018-2023)
  • Table 99. Rest of Europe Human Microbiome, by Disease USD Million (2018-2023)
  • Table 100. Rest of Europe Human Microbiome, by Technology USD Million (2018-2023)
  • Table 101. MEA Human Microbiome, by Country USD Million (2018-2023)
  • Table 102. MEA Human Microbiome, by Type USD Million (2018-2023)
  • Table 103. MEA Human Microbiome, by Application USD Million (2018-2023)
  • Table 104. MEA Human Microbiome, by Disease USD Million (2018-2023)
  • Table 105. MEA Human Microbiome, by Technology USD Million (2018-2023)
  • Table 106. Middle East Human Microbiome, by Type USD Million (2018-2023)
  • Table 107. Middle East Human Microbiome, by Application USD Million (2018-2023)
  • Table 108. Middle East Human Microbiome, by Disease USD Million (2018-2023)
  • Table 109. Middle East Human Microbiome, by Technology USD Million (2018-2023)
  • Table 110. Africa Human Microbiome, by Type USD Million (2018-2023)
  • Table 111. Africa Human Microbiome, by Application USD Million (2018-2023)
  • Table 112. Africa Human Microbiome, by Disease USD Million (2018-2023)
  • Table 113. Africa Human Microbiome, by Technology USD Million (2018-2023)
  • Table 114. North America Human Microbiome, by Country USD Million (2018-2023)
  • Table 115. North America Human Microbiome, by Type USD Million (2018-2023)
  • Table 116. North America Human Microbiome, by Application USD Million (2018-2023)
  • Table 117. North America Human Microbiome, by Disease USD Million (2018-2023)
  • Table 118. North America Human Microbiome, by Technology USD Million (2018-2023)
  • Table 119. United States Human Microbiome, by Type USD Million (2018-2023)
  • Table 120. United States Human Microbiome, by Application USD Million (2018-2023)
  • Table 121. United States Human Microbiome, by Disease USD Million (2018-2023)
  • Table 122. United States Human Microbiome, by Technology USD Million (2018-2023)
  • Table 123. Canada Human Microbiome, by Type USD Million (2018-2023)
  • Table 124. Canada Human Microbiome, by Application USD Million (2018-2023)
  • Table 125. Canada Human Microbiome, by Disease USD Million (2018-2023)
  • Table 126. Canada Human Microbiome, by Technology USD Million (2018-2023)
  • Table 127. Mexico Human Microbiome, by Type USD Million (2018-2023)
  • Table 128. Mexico Human Microbiome, by Application USD Million (2018-2023)
  • Table 129. Mexico Human Microbiome, by Disease USD Million (2018-2023)
  • Table 130. Mexico Human Microbiome, by Technology USD Million (2018-2023)
  • Table 131. Human Microbiome Sales: by Type(M Tons)
  • Table 132. Human Microbiome Sales Probiotics , by Region M Tons (2018-2023)
  • Table 133. Human Microbiome Sales Prebiotics , by Region M Tons (2018-2023)
  • Table 134. Human Microbiome Sales Food , by Region M Tons (2018-2023)
  • Table 135. Human Microbiome Sales Medical Foods , by Region M Tons (2018-2023)
  • Table 136. Human Microbiome Sales Devices , by Region M Tons (2018-2023)
  • Table 137. Human Microbiome Sales Drugs , by Region M Tons (2018-2023)
  • Table 138. Human Microbiome Sales: by Application(M Tons)
  • Table 139. Human Microbiome Sales Therapeutics , by Region M Tons (2018-2023)
  • Table 140. Human Microbiome Sales Diagnostics , by Region M Tons (2018-2023)
  • Table 141. Human Microbiome Sales: by Disease(M Tons)
  • Table 142. Human Microbiome Sales Infectious Diseases , by Region M Tons (2018-2023)
  • Table 143. Human Microbiome Sales Endocrine and Metabolic Disorders , by Region M Tons (2018-2023)
  • Table 144. Human Microbiome Sales Inflammatory Diseases , by Region M Tons (2018-2023)
  • Table 145. Human Microbiome Sales Cancer , by Region M Tons (2018-2023)
  • Table 146. Human Microbiome Sales Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders} , by Region M Tons (2018-2023)
  • Table 147. Human Microbiome Sales: by Technology(M Tons)
  • Table 148. Human Microbiome Sales Sequencing , by Region M Tons (2018-2023)
  • Table 149. Human Microbiome Sales Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays} , by Region M Tons (2018-2023)
  • Table 150. Human Microbiome Sales Proteomics , by Region M Tons (2018-2023)
  • Table 151. Human Microbiome Sales Metabolomics , by Region M Tons (2018-2023)
  • Table 152. South America Human Microbiome Sales, by Country M Tons (2018-2023)
  • Table 153. South America Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 154. South America Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 155. South America Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 156. South America Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 157. Brazil Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 158. Brazil Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 159. Brazil Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 160. Brazil Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 161. Argentina Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 162. Argentina Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 163. Argentina Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 164. Argentina Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 165. Rest of South America Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 166. Rest of South America Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 167. Rest of South America Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 168. Rest of South America Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 169. Asia Pacific Human Microbiome Sales, by Country M Tons (2018-2023)
  • Table 170. Asia Pacific Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 171. Asia Pacific Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 172. Asia Pacific Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 173. Asia Pacific Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 174. China Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 175. China Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 176. China Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 177. China Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 178. Japan Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 179. Japan Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 180. Japan Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 181. Japan Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 182. India Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 183. India Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 184. India Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 185. India Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 186. South Korea Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 187. South Korea Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 188. South Korea Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 189. South Korea Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 190. Taiwan Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 191. Taiwan Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 192. Taiwan Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 193. Taiwan Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 194. Australia Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 195. Australia Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 196. Australia Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 197. Australia Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 198. Rest of Asia-Pacific Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 199. Rest of Asia-Pacific Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 200. Rest of Asia-Pacific Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 201. Rest of Asia-Pacific Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 202. Europe Human Microbiome Sales, by Country M Tons (2018-2023)
  • Table 203. Europe Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 204. Europe Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 205. Europe Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 206. Europe Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 207. Germany Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 208. Germany Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 209. Germany Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 210. Germany Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 211. France Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 212. France Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 213. France Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 214. France Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 215. Italy Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 216. Italy Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 217. Italy Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 218. Italy Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 219. United Kingdom Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 220. United Kingdom Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 221. United Kingdom Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 222. United Kingdom Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 223. Netherlands Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 224. Netherlands Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 225. Netherlands Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 226. Netherlands Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 227. Rest of Europe Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 228. Rest of Europe Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 229. Rest of Europe Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 230. Rest of Europe Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 231. MEA Human Microbiome Sales, by Country M Tons (2018-2023)
  • Table 232. MEA Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 233. MEA Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 234. MEA Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 235. MEA Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 236. Middle East Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 237. Middle East Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 238. Middle East Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 239. Middle East Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 240. Africa Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 241. Africa Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 242. Africa Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 243. Africa Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 244. North America Human Microbiome Sales, by Country M Tons (2018-2023)
  • Table 245. North America Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 246. North America Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 247. North America Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 248. North America Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 249. United States Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 250. United States Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 251. United States Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 252. United States Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 253. Canada Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 254. Canada Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 255. Canada Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 256. Canada Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 257. Mexico Human Microbiome Sales, by Type M Tons (2018-2023)
  • Table 258. Mexico Human Microbiome Sales, by Application M Tons (2018-2023)
  • Table 259. Mexico Human Microbiome Sales, by Disease M Tons (2018-2023)
  • Table 260. Mexico Human Microbiome Sales, by Technology M Tons (2018-2023)
  • Table 261. Human Microbiome: by Type(USD/Units)
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Human Microbiome: by Type(USD Million)
  • Table 271. Human Microbiome Probiotics , by Region USD Million (2025-2030)
  • Table 272. Human Microbiome Prebiotics , by Region USD Million (2025-2030)
  • Table 273. Human Microbiome Food , by Region USD Million (2025-2030)
  • Table 274. Human Microbiome Medical Foods , by Region USD Million (2025-2030)
  • Table 275. Human Microbiome Devices , by Region USD Million (2025-2030)
  • Table 276. Human Microbiome Drugs , by Region USD Million (2025-2030)
  • Table 277. Human Microbiome: by Application(USD Million)
  • Table 278. Human Microbiome Therapeutics , by Region USD Million (2025-2030)
  • Table 279. Human Microbiome Diagnostics , by Region USD Million (2025-2030)
  • Table 280. Human Microbiome: by Disease(USD Million)
  • Table 281. Human Microbiome Infectious Diseases , by Region USD Million (2025-2030)
  • Table 282. Human Microbiome Endocrine and Metabolic Disorders , by Region USD Million (2025-2030)
  • Table 283. Human Microbiome Inflammatory Diseases , by Region USD Million (2025-2030)
  • Table 284. Human Microbiome Cancer , by Region USD Million (2025-2030)
  • Table 285. Human Microbiome Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders} , by Region USD Million (2025-2030)
  • Table 286. Human Microbiome: by Technology(USD Million)
  • Table 287. Human Microbiome Sequencing , by Region USD Million (2025-2030)
  • Table 288. Human Microbiome Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays} , by Region USD Million (2025-2030)
  • Table 289. Human Microbiome Proteomics , by Region USD Million (2025-2030)
  • Table 290. Human Microbiome Metabolomics , by Region USD Million (2025-2030)
  • Table 291. South America Human Microbiome, by Country USD Million (2025-2030)
  • Table 292. South America Human Microbiome, by Type USD Million (2025-2030)
  • Table 293. South America Human Microbiome, by Application USD Million (2025-2030)
  • Table 294. South America Human Microbiome, by Disease USD Million (2025-2030)
  • Table 295. South America Human Microbiome, by Technology USD Million (2025-2030)
  • Table 296. Brazil Human Microbiome, by Type USD Million (2025-2030)
  • Table 297. Brazil Human Microbiome, by Application USD Million (2025-2030)
  • Table 298. Brazil Human Microbiome, by Disease USD Million (2025-2030)
  • Table 299. Brazil Human Microbiome, by Technology USD Million (2025-2030)
  • Table 300. Argentina Human Microbiome, by Type USD Million (2025-2030)
  • Table 301. Argentina Human Microbiome, by Application USD Million (2025-2030)
  • Table 302. Argentina Human Microbiome, by Disease USD Million (2025-2030)
  • Table 303. Argentina Human Microbiome, by Technology USD Million (2025-2030)
  • Table 304. Rest of South America Human Microbiome, by Type USD Million (2025-2030)
  • Table 305. Rest of South America Human Microbiome, by Application USD Million (2025-2030)
  • Table 306. Rest of South America Human Microbiome, by Disease USD Million (2025-2030)
  • Table 307. Rest of South America Human Microbiome, by Technology USD Million (2025-2030)
  • Table 308. Asia Pacific Human Microbiome, by Country USD Million (2025-2030)
  • Table 309. Asia Pacific Human Microbiome, by Type USD Million (2025-2030)
  • Table 310. Asia Pacific Human Microbiome, by Application USD Million (2025-2030)
  • Table 311. Asia Pacific Human Microbiome, by Disease USD Million (2025-2030)
  • Table 312. Asia Pacific Human Microbiome, by Technology USD Million (2025-2030)
  • Table 313. China Human Microbiome, by Type USD Million (2025-2030)
  • Table 314. China Human Microbiome, by Application USD Million (2025-2030)
  • Table 315. China Human Microbiome, by Disease USD Million (2025-2030)
  • Table 316. China Human Microbiome, by Technology USD Million (2025-2030)
  • Table 317. Japan Human Microbiome, by Type USD Million (2025-2030)
  • Table 318. Japan Human Microbiome, by Application USD Million (2025-2030)
  • Table 319. Japan Human Microbiome, by Disease USD Million (2025-2030)
  • Table 320. Japan Human Microbiome, by Technology USD Million (2025-2030)
  • Table 321. India Human Microbiome, by Type USD Million (2025-2030)
  • Table 322. India Human Microbiome, by Application USD Million (2025-2030)
  • Table 323. India Human Microbiome, by Disease USD Million (2025-2030)
  • Table 324. India Human Microbiome, by Technology USD Million (2025-2030)
  • Table 325. South Korea Human Microbiome, by Type USD Million (2025-2030)
  • Table 326. South Korea Human Microbiome, by Application USD Million (2025-2030)
  • Table 327. South Korea Human Microbiome, by Disease USD Million (2025-2030)
  • Table 328. South Korea Human Microbiome, by Technology USD Million (2025-2030)
  • Table 329. Taiwan Human Microbiome, by Type USD Million (2025-2030)
  • Table 330. Taiwan Human Microbiome, by Application USD Million (2025-2030)
  • Table 331. Taiwan Human Microbiome, by Disease USD Million (2025-2030)
  • Table 332. Taiwan Human Microbiome, by Technology USD Million (2025-2030)
  • Table 333. Australia Human Microbiome, by Type USD Million (2025-2030)
  • Table 334. Australia Human Microbiome, by Application USD Million (2025-2030)
  • Table 335. Australia Human Microbiome, by Disease USD Million (2025-2030)
  • Table 336. Australia Human Microbiome, by Technology USD Million (2025-2030)
  • Table 337. Rest of Asia-Pacific Human Microbiome, by Type USD Million (2025-2030)
  • Table 338. Rest of Asia-Pacific Human Microbiome, by Application USD Million (2025-2030)
  • Table 339. Rest of Asia-Pacific Human Microbiome, by Disease USD Million (2025-2030)
  • Table 340. Rest of Asia-Pacific Human Microbiome, by Technology USD Million (2025-2030)
  • Table 341. Europe Human Microbiome, by Country USD Million (2025-2030)
  • Table 342. Europe Human Microbiome, by Type USD Million (2025-2030)
  • Table 343. Europe Human Microbiome, by Application USD Million (2025-2030)
  • Table 344. Europe Human Microbiome, by Disease USD Million (2025-2030)
  • Table 345. Europe Human Microbiome, by Technology USD Million (2025-2030)
  • Table 346. Germany Human Microbiome, by Type USD Million (2025-2030)
  • Table 347. Germany Human Microbiome, by Application USD Million (2025-2030)
  • Table 348. Germany Human Microbiome, by Disease USD Million (2025-2030)
  • Table 349. Germany Human Microbiome, by Technology USD Million (2025-2030)
  • Table 350. France Human Microbiome, by Type USD Million (2025-2030)
  • Table 351. France Human Microbiome, by Application USD Million (2025-2030)
  • Table 352. France Human Microbiome, by Disease USD Million (2025-2030)
  • Table 353. France Human Microbiome, by Technology USD Million (2025-2030)
  • Table 354. Italy Human Microbiome, by Type USD Million (2025-2030)
  • Table 355. Italy Human Microbiome, by Application USD Million (2025-2030)
  • Table 356. Italy Human Microbiome, by Disease USD Million (2025-2030)
  • Table 357. Italy Human Microbiome, by Technology USD Million (2025-2030)
  • Table 358. United Kingdom Human Microbiome, by Type USD Million (2025-2030)
  • Table 359. United Kingdom Human Microbiome, by Application USD Million (2025-2030)
  • Table 360. United Kingdom Human Microbiome, by Disease USD Million (2025-2030)
  • Table 361. United Kingdom Human Microbiome, by Technology USD Million (2025-2030)
  • Table 362. Netherlands Human Microbiome, by Type USD Million (2025-2030)
  • Table 363. Netherlands Human Microbiome, by Application USD Million (2025-2030)
  • Table 364. Netherlands Human Microbiome, by Disease USD Million (2025-2030)
  • Table 365. Netherlands Human Microbiome, by Technology USD Million (2025-2030)
  • Table 366. Rest of Europe Human Microbiome, by Type USD Million (2025-2030)
  • Table 367. Rest of Europe Human Microbiome, by Application USD Million (2025-2030)
  • Table 368. Rest of Europe Human Microbiome, by Disease USD Million (2025-2030)
  • Table 369. Rest of Europe Human Microbiome, by Technology USD Million (2025-2030)
  • Table 370. MEA Human Microbiome, by Country USD Million (2025-2030)
  • Table 371. MEA Human Microbiome, by Type USD Million (2025-2030)
  • Table 372. MEA Human Microbiome, by Application USD Million (2025-2030)
  • Table 373. MEA Human Microbiome, by Disease USD Million (2025-2030)
  • Table 374. MEA Human Microbiome, by Technology USD Million (2025-2030)
  • Table 375. Middle East Human Microbiome, by Type USD Million (2025-2030)
  • Table 376. Middle East Human Microbiome, by Application USD Million (2025-2030)
  • Table 377. Middle East Human Microbiome, by Disease USD Million (2025-2030)
  • Table 378. Middle East Human Microbiome, by Technology USD Million (2025-2030)
  • Table 379. Africa Human Microbiome, by Type USD Million (2025-2030)
  • Table 380. Africa Human Microbiome, by Application USD Million (2025-2030)
  • Table 381. Africa Human Microbiome, by Disease USD Million (2025-2030)
  • Table 382. Africa Human Microbiome, by Technology USD Million (2025-2030)
  • Table 383. North America Human Microbiome, by Country USD Million (2025-2030)
  • Table 384. North America Human Microbiome, by Type USD Million (2025-2030)
  • Table 385. North America Human Microbiome, by Application USD Million (2025-2030)
  • Table 386. North America Human Microbiome, by Disease USD Million (2025-2030)
  • Table 387. North America Human Microbiome, by Technology USD Million (2025-2030)
  • Table 388. United States Human Microbiome, by Type USD Million (2025-2030)
  • Table 389. United States Human Microbiome, by Application USD Million (2025-2030)
  • Table 390. United States Human Microbiome, by Disease USD Million (2025-2030)
  • Table 391. United States Human Microbiome, by Technology USD Million (2025-2030)
  • Table 392. Canada Human Microbiome, by Type USD Million (2025-2030)
  • Table 393. Canada Human Microbiome, by Application USD Million (2025-2030)
  • Table 394. Canada Human Microbiome, by Disease USD Million (2025-2030)
  • Table 395. Canada Human Microbiome, by Technology USD Million (2025-2030)
  • Table 396. Mexico Human Microbiome, by Type USD Million (2025-2030)
  • Table 397. Mexico Human Microbiome, by Application USD Million (2025-2030)
  • Table 398. Mexico Human Microbiome, by Disease USD Million (2025-2030)
  • Table 399. Mexico Human Microbiome, by Technology USD Million (2025-2030)
  • Table 400. Human Microbiome Sales: by Type(M Tons)
  • Table 401. Human Microbiome Sales Probiotics , by Region M Tons (2025-2030)
  • Table 402. Human Microbiome Sales Prebiotics , by Region M Tons (2025-2030)
  • Table 403. Human Microbiome Sales Food , by Region M Tons (2025-2030)
  • Table 404. Human Microbiome Sales Medical Foods , by Region M Tons (2025-2030)
  • Table 405. Human Microbiome Sales Devices , by Region M Tons (2025-2030)
  • Table 406. Human Microbiome Sales Drugs , by Region M Tons (2025-2030)
  • Table 407. Human Microbiome Sales: by Application(M Tons)
  • Table 408. Human Microbiome Sales Therapeutics , by Region M Tons (2025-2030)
  • Table 409. Human Microbiome Sales Diagnostics , by Region M Tons (2025-2030)
  • Table 410. Human Microbiome Sales: by Disease(M Tons)
  • Table 411. Human Microbiome Sales Infectious Diseases , by Region M Tons (2025-2030)
  • Table 412. Human Microbiome Sales Endocrine and Metabolic Disorders , by Region M Tons (2025-2030)
  • Table 413. Human Microbiome Sales Inflammatory Diseases , by Region M Tons (2025-2030)
  • Table 414. Human Microbiome Sales Cancer , by Region M Tons (2025-2030)
  • Table 415. Human Microbiome Sales Other Diseases {Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders} , by Region M Tons (2025-2030)
  • Table 416. Human Microbiome Sales: by Technology(M Tons)
  • Table 417. Human Microbiome Sales Sequencing , by Region M Tons (2025-2030)
  • Table 418. Human Microbiome Sales Genomic Technologies {Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays} , by Region M Tons (2025-2030)
  • Table 419. Human Microbiome Sales Proteomics , by Region M Tons (2025-2030)
  • Table 420. Human Microbiome Sales Metabolomics , by Region M Tons (2025-2030)
  • Table 421. South America Human Microbiome Sales, by Country M Tons (2025-2030)
  • Table 422. South America Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 423. South America Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 424. South America Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 425. South America Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 426. Brazil Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 427. Brazil Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 428. Brazil Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 429. Brazil Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 430. Argentina Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 431. Argentina Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 432. Argentina Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 433. Argentina Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 434. Rest of South America Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 435. Rest of South America Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 436. Rest of South America Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 437. Rest of South America Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 438. Asia Pacific Human Microbiome Sales, by Country M Tons (2025-2030)
  • Table 439. Asia Pacific Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 440. Asia Pacific Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 441. Asia Pacific Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 442. Asia Pacific Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 443. China Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 444. China Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 445. China Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 446. China Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 447. Japan Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 448. Japan Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 449. Japan Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 450. Japan Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 451. India Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 452. India Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 453. India Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 454. India Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 455. South Korea Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 456. South Korea Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 457. South Korea Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 458. South Korea Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 459. Taiwan Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 460. Taiwan Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 461. Taiwan Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 462. Taiwan Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 463. Australia Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 464. Australia Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 465. Australia Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 466. Australia Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 467. Rest of Asia-Pacific Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 468. Rest of Asia-Pacific Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 469. Rest of Asia-Pacific Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 470. Rest of Asia-Pacific Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 471. Europe Human Microbiome Sales, by Country M Tons (2025-2030)
  • Table 472. Europe Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 473. Europe Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 474. Europe Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 475. Europe Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 476. Germany Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 477. Germany Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 478. Germany Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 479. Germany Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 480. France Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 481. France Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 482. France Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 483. France Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 484. Italy Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 485. Italy Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 486. Italy Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 487. Italy Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 488. United Kingdom Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 489. United Kingdom Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 490. United Kingdom Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 491. United Kingdom Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 492. Netherlands Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 493. Netherlands Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 494. Netherlands Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 495. Netherlands Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 496. Rest of Europe Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 497. Rest of Europe Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 498. Rest of Europe Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 499. Rest of Europe Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 500. MEA Human Microbiome Sales, by Country M Tons (2025-2030)
  • Table 501. MEA Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 502. MEA Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 503. MEA Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 504. MEA Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 505. Middle East Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 506. Middle East Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 507. Middle East Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 508. Middle East Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 509. Africa Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 510. Africa Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 511. Africa Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 512. Africa Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 513. North America Human Microbiome Sales, by Country M Tons (2025-2030)
  • Table 514. North America Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 515. North America Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 516. North America Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 517. North America Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 518. United States Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 519. United States Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 520. United States Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 521. United States Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 522. Canada Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 523. Canada Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 524. Canada Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 525. Canada Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 526. Mexico Human Microbiome Sales, by Type M Tons (2025-2030)
  • Table 527. Mexico Human Microbiome Sales, by Application M Tons (2025-2030)
  • Table 528. Mexico Human Microbiome Sales, by Disease M Tons (2025-2030)
  • Table 529. Mexico Human Microbiome Sales, by Technology M Tons (2025-2030)
  • Table 530. Human Microbiome: by Type(USD/Units)
  • Table 531. Research Programs/Design for This Report
  • Table 532. Key Data Information from Secondary Sources
  • Table 533. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Microbiome: by Type USD Million (2018-2023)
  • Figure 5. Global Human Microbiome: by Application USD Million (2018-2023)
  • Figure 6. Global Human Microbiome: by Disease USD Million (2018-2023)
  • Figure 7. Global Human Microbiome: by Technology USD Million (2018-2023)
  • Figure 8. South America Human Microbiome Share (%), by Country
  • Figure 9. Asia Pacific Human Microbiome Share (%), by Country
  • Figure 10. Europe Human Microbiome Share (%), by Country
  • Figure 11. MEA Human Microbiome Share (%), by Country
  • Figure 12. North America Human Microbiome Share (%), by Country
  • Figure 13. Global Human Microbiome: by Type M Tons (2018-2023)
  • Figure 14. Global Human Microbiome: by Application M Tons (2018-2023)
  • Figure 15. Global Human Microbiome: by Disease M Tons (2018-2023)
  • Figure 16. Global Human Microbiome: by Technology M Tons (2018-2023)
  • Figure 17. South America Human Microbiome Share (%), by Country
  • Figure 18. Asia Pacific Human Microbiome Share (%), by Country
  • Figure 19. Europe Human Microbiome Share (%), by Country
  • Figure 20. MEA Human Microbiome Share (%), by Country
  • Figure 21. North America Human Microbiome Share (%), by Country
  • Figure 22. Global Human Microbiome: by Type USD/Units (2018-2023)
  • Figure 23. Global Human Microbiome share by Players 2023 (%)
  • Figure 24. Global Human Microbiome share by Players (Top 3) 2023(%)
  • Figure 25. Global Human Microbiome share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Seres Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 28. Seres Therapeutics (United States) Revenue: by Geography 2023
  • Figure 29. Pharma PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Pharma PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 31. UBiome (United States) Revenue, Net Income and Gross profit
  • Figure 32. UBiome (United States) Revenue: by Geography 2023
  • Figure 33. E.I. du Pont de Nemours and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. E.I. du Pont de Nemours and Company (United States) Revenue: by Geography 2023
  • Figure 35. Synlogic (United States) Revenue, Net Income and Gross profit
  • Figure 36. Synlogic (United States) Revenue: by Geography 2023
  • Figure 37. Second Genome (United States) Revenue, Net Income and Gross profit
  • Figure 38. Second Genome (United States) Revenue: by Geography 2023
  • Figure 39. Vedanta Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 40. Vedanta Biosciences (United States) Revenue: by Geography 2023
  • Figure 41. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2023
  • Figure 43. Global Human Microbiome: by Type USD Million (2025-2030)
  • Figure 44. Global Human Microbiome: by Application USD Million (2025-2030)
  • Figure 45. Global Human Microbiome: by Disease USD Million (2025-2030)
  • Figure 46. Global Human Microbiome: by Technology USD Million (2025-2030)
  • Figure 47. South America Human Microbiome Share (%), by Country
  • Figure 48. Asia Pacific Human Microbiome Share (%), by Country
  • Figure 49. Europe Human Microbiome Share (%), by Country
  • Figure 50. MEA Human Microbiome Share (%), by Country
  • Figure 51. North America Human Microbiome Share (%), by Country
  • Figure 52. Global Human Microbiome: by Type M Tons (2025-2030)
  • Figure 53. Global Human Microbiome: by Application M Tons (2025-2030)
  • Figure 54. Global Human Microbiome: by Disease M Tons (2025-2030)
  • Figure 55. Global Human Microbiome: by Technology M Tons (2025-2030)
  • Figure 56. South America Human Microbiome Share (%), by Country
  • Figure 57. Asia Pacific Human Microbiome Share (%), by Country
  • Figure 58. Europe Human Microbiome Share (%), by Country
  • Figure 59. MEA Human Microbiome Share (%), by Country
  • Figure 60. North America Human Microbiome Share (%), by Country
  • Figure 61. Global Human Microbiome: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Seres Therapeutics (United States)
  • Pharma PLC (United Kingdom)
  • UBiome (United States)
  • E.I. du Pont de Nemours and Company (United States)
  • Synlogic (United States)
  • Second Genome (United States)
  • Vedanta Biosciences (United States)
  • Ferring Pharmaceuticals (Switzerland)
Additional players considered in the study are as follows:
Evelo Biosciences (United States) , ViThera Pharmaceuticals (United States) , BiomX (Israel) , LNC Therapeutics (France)
Select User Access Type

Key Highlights of Report


Mar 2024 233 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Microbiome Quantitative research analysis
Global Human Microbiome Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Seres Therapeutics (United States), Pharma PLC (United Kingdom), UBiome (United States), E.I. du Pont de Nemours and Company (United States), Synlogic (United States), Second Genome (United States), Vedanta Biosciences (United States) and Ferring Pharmaceuticals (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Number of Microbiome-Based Drug Pipeline Across the Worldwide" is seen as one of major influencing trends for Human Microbiome Market during projected period 2023-2030.
The Human Microbiome market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Human Microbiome Report?

Have a Query? Click Here

Other Related Reports

Pharmaceutical Vials Comprehensive Study by Type (Screw Thread Glass Vials, Plastic Stoppered Display Glass Vials, Serum Glass Vials, Polyethylene HDPE, Polyethylene terephthalate, Polystyrene, (PS, ...
$ 3650
Parenteral Nutrition Comprehensive Study by Type (Carbohydrates, Parenteral Lipid Emulsion, Single Dose Amino Acid Solutions, Trace Elements, Electrolytes, Vitamins and Minerals), Application (Premat...
$ 3650
Pediatric Nutrition Comprehensive Study by Type (Milk-based, Soy-based, Organic, Others), Application (Brain Development, Nutrition Source, Metabolic Disorders, Allergy Management), Formulation Type ...
$ 3450
RNAi for Therapeutic Comprehensive Study by Type (Small interfering RNAs (siRNA), Short hairpin RNAs (shRNA)), Application (Neurodegenerative Disease, Cardiovascular Disease, Viral Infection, RNAi-Ba...
$ 4500
Infection Control Comprehensive Study by Type (Hand Disinfectants, Skin Disinfectants, Instrument Disinfectants, Surface Disinfectants), Application (Hospitals & Clinics, Life Sciences Industry, Medi...
$ 3750
Monoclonal Antibody Based Products Comprehensive Study by Type (Murine, Chimeric, Humanized, Human), Application (Therapeutics, Diagnostics), Diseases Type (Non-communicable Diseases, Infectious Dise...
$ 3800